{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:16:50Z","timestamp":1793218610965,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejim.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T07:28:01Z","timestamp":1657351681000},"page":"49-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6818-7666","authenticated-orcid":false,"given":"Gian Luca","family":"Erre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-4462","authenticated-orcid":false,"given":"Fabio","family":"Cacciapaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1849-5123","authenticated-orcid":false,"given":"Garifallia","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreina","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-1412","authenticated-orcid":false,"given":"Arduino Aleksander","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard John","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Lucia","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gremese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cafaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Nucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Vacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1969-2097","authenticated-orcid":false,"given":"Francesca Romana","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejim.2022.07.001_bib0001","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","article-title":"Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies","volume":"48","author":"Meune","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejim.2022.07.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2020.104038","article-title":"Comprehensive arginine metabolomics and peripheral vasodilatory capacity in rheumatoid arthritis: a monocentric cross-sectional study","volume":"131","author":"Erre","year":"2020","journal-title":"Microvasc Res"},{"issue":"17","key":"10.1016\/j.ejim.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.3390\/molecules25173855","article-title":"Oxidative stress biomarkers and peripheral endothelial dysfunction in rheumatoid arthritis: a monocentric cross-sectional case-control study","volume":"25","author":"Bassu","year":"2020","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.ejim.2022.07.001_bib0004","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.2174\/1381612827666210106144247","article-title":"Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?","volume":"27","author":"Mangoni","year":"2021","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejim.2022.07.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6548715","article-title":"Prevalence and determinants of peripheral microvascular endothelial dysfunction in rheumatoid arthritis patients: a multicenter cross-sectional study","author":"Erre","year":"2018","journal-title":"Mediators Inflamm"},{"issue":"7","key":"10.1016\/j.ejim.2022.07.001_bib0006","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00296-018-4039-8","article-title":"Coronary flow reserve in systemic rheumatic diseases: a systematic review and meta-analysis","volume":"38","author":"Erre","year":"2018","journal-title":"Rheumatol Int"},{"issue":"1_suppl","key":"10.1016\/j.ejim.2022.07.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/0300060515593255","article-title":"Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: a case\u2013control study","volume":"44","author":"Erre","year":"2016","journal-title":"J Int Med Res"},{"issue":"3","key":"10.1016\/j.ejim.2022.07.001_bib0008","first-page":"516","article-title":"QT and QT dispersion intervals in long-standing and moderately active rheumatoid arthritis: results from a multicentre cross-sectional study","volume":"38","author":"Erre","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.ejim.2022.07.001_bib0009","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3899\/jrheum.200842","article-title":"Improved incidence of cardiovascular disease in patients with incident rheumatoid arthritis in the 2000s: a population-based cohort study","volume":"48","author":"Myasoedova","year":"2021","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.ejim.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2016-209562","article-title":"Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap","volume":"76","author":"Lacaille","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2022.07.001_bib0011","doi-asserted-by":"crossref","unstructured":"Dhindsa D.S., Sandesara P.B., Shapiro M.D., Wong N.D. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7(May). doi:10.3389\/fcvm.2020.00088.","DOI":"10.3389\/fcvm.2020.00088"},{"issue":"February","key":"10.1016\/j.ejim.2022.07.001_bib0012","first-page":"1","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"21","key":"10.1016\/j.ejim.2022.07.001_bib0013","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jcm10214975","article-title":"Moderate and high disease activity predicts the development of carotid plaque in rheumatoid arthritis patients without classic cardiovascular risk factors: six years follow-up study","volume":"10","author":"Ferraz-Amaro","year":"2021","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.ejim.2022.07.001_bib0014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.ejim.2022.07.001_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semarthrit.2020.11.005","article-title":"C-reactive protein and implications in rheumatoid arthritis and associated comorbidities","volume":"51","author":"Pope","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ejim.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatol U K"},{"issue":"7","key":"10.1016\/j.ejim.2022.07.001_bib0017","first-page":"1219","article-title":"High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis","volume":"32","author":"Gonzalez-Gay","year":"2005","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ejim.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.22482","article-title":"HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis","volume":"57","author":"Gonzalez-Gay","year":"2007","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.ejim.2022.07.001_bib0019","article-title":"Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group","author":"Cacciapaglia","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"9","key":"10.1016\/j.ejim.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"14","key":"10.1016\/j.ejim.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.ejim.2022.07.001_bib0022","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ejim.2022.07.001_bib0023","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ejim.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort","volume":"52","author":"Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ejim.2022.07.001_bib0025","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/ard.2010.135871","article-title":"Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease","volume":"70","author":"Myasoedova","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ejim.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.CIR.0000080289.72166.CF","article-title":"Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score","volume":"108","author":"Albert","year":"2003","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ejim.2022.07.001_bib0027","first-page":"973","article-title":"Inflammation, aspirin and the risk of cardiovascular disease in apparentrly healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"October"},{"issue":"12","key":"10.1016\/j.ejim.2022.07.001_bib0028","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"issue":"39","key":"10.1016\/j.ejim.2022.07.001_bib0030","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.2174\/1381612825666191112091700","article-title":"Methotrexate and vasculoprotection: mechanistic insights and potential therapeutic applications in old age","volume":"25","author":"Mangoni","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejim.2022.07.001_bib0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fcvm.2021.681327","article-title":"Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis","volume":"8","author":"Mangoni","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2022.07.001_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212557","article-title":"Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate","volume":"7","author":"Mangoni","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.ejim.2022.07.001_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/9632846","article-title":"Protective effects of methotrexate against proatherosclerotic cytokines: a review of the evidence","volume":"2017","author":"Mangoni","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"12","key":"10.1016\/j.ejim.2022.07.001_bib0034","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejim.2022.07.001_bib0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522002515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522002515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:38:04Z","timestamp":1760607484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620522002515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"alternative-id":["S0953620522002515"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.07.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}